Evidence Hub

Anti-inflammatory and antinociceptive effects of sitagliptin in animal models and possible mechanisms involved in the antinociceptive activity

Valiollah Hajhashemi, Hossein Sadeghi, Fatemeh Karimi Madab

The Korean journal of pain, 2023

6 citations

Abstract

Background: Sitagliptin is an antidiabetic drug that inhibits dipeptidyl peptidase-4 enzyme.This study aimed to investigate the antinociceptive and anti-inflammatory effects of sitagliptin in formalin and carrageenan tests and determine the possible mechanism(s) of its antinociceptive activity.Methods: Male Swiss mice (25-30 g) and male Wistar rats (180-220 g) were used for formalin and carrageenan tests, respectively.In the formalin test, paw licking time and in the carrageenan test, paw thickness were considered as indexes of pain behavior and inflammation respectively.Three doses of sitagliptin (2.5, 5, and 10 mg/kg) were used in these tests.Also, several antagonists and enzyme inhibitors were used to evaluate the role of adrenergic, serotonergic, dopaminergic, and opioid receptors as well as the NO/cGMP/K ATP pathway in the antinociceptive effect of sitagliptin (5 mg/kg).Results: Sitagliptin showed significant antinociceptive and anti-inflammatory effects in the formalin and carrageenan tests respectively.In the carrageenan test, all three doses of sitagliptin significantly (P < 0.001) reduced paw thickness.Pretreatment with yohimbine, prazosin, propranolol, naloxone, and cyproheptadine could not reverse the antinociceptive effect of sitagliptin (5 mg/Kg), which indicates that adrenergic, opioid, and serotonin receptors (5HT 2 ) are not involved in the antinociceptive effects.L-NAME, methylene blue, glibenclamide, ondansetron, and sulpiride were able to reverse this…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free